Skip Navigation
KO EN JP CN
Intellectual Property Careers
Menu
Intellectual Property Careers
Locations Contacts
Close
Search

Inje KANG Attorney

T.+82-2-3703-4760 F.+82-2-737-9091/9092
Inje KANG Attorney
pdfvcardprint
Inje KANG Attorney

Inje KANGAttorney

T.+82-2-3703-4760 F.+82-2-737-9091/9092 E.inje.kang@kimchang.com

PDF Vcard

Areas of Expertise

Bio

Inje Kang is an attorney at Kim & Chang who specializes in the areas of corporate compliance consulting, internal investigation and anti-corruption. He also has various work experiences in digital forensics and legal tech, and AI/IT-based compliance monitoring systems, such as the establishment of a continuous IT monitoring system.

Mr. Kang possesses extensive experience in establishing and strengthening compliance systems for corporations and providing relevant improvement measures. He has successfully established and strengthened compliance systems for companies in the chemical, food, tourism, technology, distribution, machinery, automobile, steel, defense, electronics, pharmaceutical and heavy industries.

Employing his in-depth knowledge of the health industry, which incorporates the pharmaceutical, medical device, food and cosmetics industries, Mr. Kang has advised on matters relating to industry-specific regulations, fair trade, advertising, labor and employment, mergers and acquisitions and distribution. He has also represented multiple global companies before the Korean regulators, such as the Prosecutors’ Office and the Korea Fair Trade Commission, on a diverse range of cases.

In particular, Mr. Kang shows excellent expertise in projects where effective and legitimate advice can be provided only after obtaining a full understanding of the business characteristics, size, corporate culture and current situation of the business.

Based on his outstanding presentation skills, Mr. Kang gives lectures on compliance, ESG, anti-corruption and industry specific regulations to a number of client companies, universities, Thomson Reuters, the Korea Human Resource Development Institute, the Korea Research-Based Pharma Industry Association, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and other institutions and organizations, and actively participates in external activities.

View All

Profile

Experience

Kim & Chang (2015-Present)
 

Representative Mattersshow

Compliance Consulting
 
  • Advised on the effectiveness check and improvement strategies for compliance programs of major domestic and international companies.
  • Provided consulting services on the compliance status of overseas subsidiaries of major domestic and international companies.
  • Advised on establishing Compliance SOPs for global pharmaceutical, distribution, chemical and consumer goods companies.
  • Advised on building an AI/IT-based continuous compliance monitoring system for domestic companies.
  • Advised major domestic and international corporations on building and strengthening comprehensive compliance systems.
          - Advised on risk diagnosis (Risk Mapping) and improvement.
         - Advised on strengthening employee training systems.
         - Advised on improving internal policies and enhancing work procedures (including Process Innovation).
         - Advised on reinforcing internal audit systems.
         - Advised on Compliance Self-Diagnosis Toolkits (covering multiple areas including anti-corruption, fair trade, trade secrets and labor relations).
         - Advised on strengthening internal reporting systems.
         - Evaluated the effectiveness of compliance control standards.
         - Advised on responding to regulatory changes related to directors’ compliance oversight obligations.

 
Anti-Corruption and Corporate Compliance
 
  • Advised on responding to investigations by regulatory authorities overseas for major domestic and international companies.
  • Advised on establishing FCPA risk management systems (including third-party agent management processes) for major domestic and international companies.
  • Advised on conducting internal investigations for major domestic and international companies.
  • Advised on responding to investigations by the Anti-Corruption and Civil Rights Commission regarding violations of the Improper Solicitation and Graft Act.
  • Advised on responding to investigations by prosecutors and the police regarding corruption allegations under the Criminal Code and the Improper Solicitation and Graft Act.

Healthcare
 
  • Advised on unique regulatory issues related to the Pharmaceutical Affairs Act and Medical Device Act for major domestic pharmaceutical and medical device companies.
  • Advised on executing regulatory improvement, relaxation and legislative amendment projects for major domestic pharmaceutical and medical device companies.
  • Advised on responding to police and prosecution investigations related to the double penalty system for rebates.
  • Advised on responding to investigations by the Fair Trade Commission regarding unfair trading practices in the pharmaceutical and medical device sectors.
  • Advised on responding to investigations regarding unfair joint actions and obstruction of business operations by the Fair Trade Commission.
  • Advised on responding to administrative actions related to violations of the Pharmaceutical Affairs Act and Medical Device Act.
  • Advised on developing IT solutions for expenditure reporting in accordance with the Pharmaceutical Affairs Act and Medical Device Act, integrated with existing corporate IT systems.
  • Advised on establishing product safety management systems for domestic conglomerates.

Representative Activitiesshow

Publications/Activities
    • "Corporate Legal Risk Response Measures Related to Anti-Corruption", Enterprise-wide Risk Management Course (Law&Bi Education Center, 2024)
    • "Compliance and AI: Global Trends and Noteworthy Issues" Presentation, KRPIA EBP Annual Workshop (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2024)
    • "Practical Training on Building and Strengthening Compliance Control Systems", Internal Audit Specialized Training (Korea Audit Association, 2024)
    • "Analysis of Rebate Types and Corporate Response Strategies," Presentation at the 2023 Pharmaceutical Industry Ethics Management Academy (Jointly organized by the Korea Association of Global Pharmaceutical Industry and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2023)
    • "Corporate Legal Risk Response Strategies Related to Corruption Prevention," Special Lecture Course Established (LAWnB Education Center, 2023)
    • "Law and Ethics Based on ESG," Presentation at the Sogang University ESG Leadership Program (Sogang University, 2021, 2022, 2023)
    • "Key Considerations in Tax Audits Focused on Clinical Trial Support Costs," Presentation at the 2022 Ethics Management Workshop of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2022)
    • "Internal Risk & External Crisis in Crisis Management Response," 2020 KRPIA Ethics Management Online Workshop (Korea Association of Global Pharmaceutical Industry, 2020)
    • "Recent Compliance Trends in the Pharmaceutical Industry and Responses," Presentation at the 2020 Pharmaceutical Industry Ethics Management Academy & Workshop (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2020)
    • "Managing Legal Risks Related to Corruption Prevention," Lecture (Thomson Reuters/LAWnB, 2018)
    • "Second Specialized Training Course on Prevention of Rebates and Fair Trade in Pharmaceuticals and Medical Devices," Lecture Course Established (Korea Health and Welfare Human Resources Development Institute, 2018)
    • "Regulatory Trends in the Healthcare Industry and Corporate Responses," Lecture at the IHCF Healthcare Subcommittee Seminar (In-House Counsel Forum, 2017)
    • "Main Contents of the Expenditure Reporting Guidelines, Anticipated Issues, and Response Strategies," Presentation at the KRPIA EBP Workshop (Korea Association of Global Pharmaceutical Industry, 2017)
    • "Key Points and Implications of Amendments to the Fair Competition Code," Presentation at the 2017 KMDIA Ethics Committee Workshop (Korea Medical Device Industry Association, 2017)
    • "Briefing on the Anti-Bribery Act (Kim Young-ran Act) for the Medical Device Industry," Presentation (Korea Medical Device Industry Association, 2016) and numerous others

Education

    University of San Diego School of Law (Visiting Scholar, 2023)

    Judicial Research and Training Institute of the Supreme Court of Korea (2015)

    Seoul National University (B.A., Major in Korean History and Minor in Law, 2010)

Qualifications

    Admitted to bar, Korea, 2015

    ISO 37001 ABMS (anti-bribery management system) Certification Institute, 2017

Languages

Korean and English

Insights

View More

Search Professionals

EXPERTISE RESET SEARCH

EXPERTISE

Close

EXPERTISE

Regulatory & Compliance Close

Advisory & Transaction show

Dispute Resolution show

레이어 닫기

Share

Close
  

Inje KANG
Attorney


T. +82-2-3703-4760      
F. +82-2-737-9091/9092      
  




Inje Kang is an attorney at Kim & Chang who specializes in the areas of corporate compliance consulting, internal investigation and anti-corruption. He also has various work experiences in digital forensics and legal tech, and AI/IT-based compliance monitoring systems, such as the establishment of a continuous IT monitoring system.

Mr. Kang possesses extensive experience in establishing and strengthening compliance systems for corporations and providing relevant improvement measures. He has successfully established and strengthened compliance systems for companies in the chemical, food, tourism, technology, distribution, machinery, automobile, steel, defense, electronics, pharmaceutical and heavy industries.

Employing his in-depth knowledge of the health industry, which incorporates the pharmaceutical, medical device, food and cosmetics industries, Mr. Kang has advised on matters relating to industry-specific regulations, fair trade, advertising, labor and employment, mergers and acquisitions and distribution. He has also represented multiple global companies before the Korean regulators, such as the Prosecutors’ Office and the Korea Fair Trade Commission, on a diverse range of cases.

In particular, Mr. Kang shows excellent expertise in projects where effective and legitimate advice can be provided only after obtaining a full understanding of the business characteristics, size, corporate culture and current situation of the business.

Based on his outstanding presentation skills, Mr. Kang gives lectures on compliance, ESG, anti-corruption and industry specific regulations to a number of client companies, universities, Thomson Reuters, the Korea Human Resource Development Institute, the Korea Research-Based Pharma Industry Association, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and other institutions and organizations, and actively participates in external activities.






    Kim & Chang (2015-Present)
     






Compliance Consulting
 
  •   Advised on the effectiveness check and improvement strategies for compliance programs of major domestic and international companies.
  •   Provided consulting services on the compliance status of overseas subsidiaries of major domestic and international companies.
  •   Advised on establishing Compliance SOPs for global pharmaceutical, distribution, chemical and consumer goods companies.
  •   Advised on building an AI/IT-based continuous compliance monitoring system for domestic companies.
  •   Advised major domestic and international corporations on building and strengthening comprehensive compliance systems.
          - Advised on risk diagnosis (Risk Mapping) and improvement.
         - Advised on strengthening employee training systems.
         - Advised on improving internal policies and enhancing work procedures (including Process Innovation).
         - Advised on reinforcing internal audit systems.
         - Advised on Compliance Self-Diagnosis Toolkits (covering multiple areas including anti-corruption, fair trade, trade secrets and labor relations).
         - Advised on strengthening internal reporting systems.
         - Evaluated the effectiveness of compliance control standards.
         - Advised on responding to regulatory changes related to directors’ compliance oversight obligations.

 
Anti-Corruption and Corporate Compliance
 
  •   Advised on responding to investigations by regulatory authorities overseas for major domestic and international companies.
  •   Advised on establishing FCPA risk management systems (including third-party agent management processes) for major domestic and international companies.
  •   Advised on conducting internal investigations for major domestic and international companies.
  •   Advised on responding to investigations by the Anti-Corruption and Civil Rights Commission regarding violations of the Improper Solicitation and Graft Act.
  •   Advised on responding to investigations by prosecutors and the police regarding corruption allegations under the Criminal Code and the Improper Solicitation and Graft Act.

Healthcare
 
  •   Advised on unique regulatory issues related to the Pharmaceutical Affairs Act and Medical Device Act for major domestic pharmaceutical and medical device companies.
  •   Advised on executing regulatory improvement, relaxation and legislative amendment projects for major domestic pharmaceutical and medical device companies.
  •   Advised on responding to police and prosecution investigations related to the double penalty system for rebates.
  •   Advised on responding to investigations by the Fair Trade Commission regarding unfair trading practices in the pharmaceutical and medical device sectors.
  •   Advised on responding to investigations regarding unfair joint actions and obstruction of business operations by the Fair Trade Commission.
  •   Advised on responding to administrative actions related to violations of the Pharmaceutical Affairs Act and Medical Device Act.
  •   Advised on developing IT solutions for expenditure reporting in accordance with the Pharmaceutical Affairs Act and Medical Device Act, integrated with existing corporate IT systems.
  •   Advised on establishing product safety management systems for domestic conglomerates.





Publications/Activities

  •   "Corporate Legal Risk Response Measures Related to Anti-Corruption", Enterprise-wide Risk Management Course (Law&Bi Education Center, 2024)
  •   "Compliance and AI: Global Trends and Noteworthy Issues" Presentation, KRPIA EBP Annual Workshop (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2024)
  •   "Practical Training on Building and Strengthening Compliance Control Systems", Internal Audit Specialized Training (Korea Audit Association, 2024)
  •   "Analysis of Rebate Types and Corporate Response Strategies," Presentation at the 2023 Pharmaceutical Industry Ethics Management Academy (Jointly organized by the Korea Association of Global Pharmaceutical Industry and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2023)
  •   "Corporate Legal Risk Response Strategies Related to Corruption Prevention," Special Lecture Course Established (LAWnB Education Center, 2023)
  •   "Law and Ethics Based on ESG," Presentation at the Sogang University ESG Leadership Program (Sogang University, 2021, 2022, 2023)
  •   "Key Considerations in Tax Audits Focused on Clinical Trial Support Costs," Presentation at the 2022 Ethics Management Workshop of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2022)
  •   "Internal Risk & External Crisis in Crisis Management Response," 2020 KRPIA Ethics Management Online Workshop (Korea Association of Global Pharmaceutical Industry, 2020)
  •   "Recent Compliance Trends in the Pharmaceutical Industry and Responses," Presentation at the 2020 Pharmaceutical Industry Ethics Management Academy & Workshop (Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 2020)
  •   "Managing Legal Risks Related to Corruption Prevention," Lecture (Thomson Reuters/LAWnB, 2018)
  •   "Second Specialized Training Course on Prevention of Rebates and Fair Trade in Pharmaceuticals and Medical Devices," Lecture Course Established (Korea Health and Welfare Human Resources Development Institute, 2018)
  •   "Regulatory Trends in the Healthcare Industry and Corporate Responses," Lecture at the IHCF Healthcare Subcommittee Seminar (In-House Counsel Forum, 2017)
  •   "Main Contents of the Expenditure Reporting Guidelines, Anticipated Issues, and Response Strategies," Presentation at the KRPIA EBP Workshop (Korea Association of Global Pharmaceutical Industry, 2017)
  •   "Key Points and Implications of Amendments to the Fair Competition Code," Presentation at the 2017 KMDIA Ethics Committee Workshop (Korea Medical Device Industry Association, 2017)
  •   "Briefing on the Anti-Bribery Act (Kim Young-ran Act) for the Medical Device Industry," Presentation (Korea Medical Device Industry Association, 2016) and numerous others





Education

    University of San Diego School of Law (Visiting Scholar, 2023)

    Judicial Research and Training Institute of the Supreme Court of Korea (2015)

    Seoul National University (B.A., Major in Korean History and Minor in Law, 2010)


Qualifications

    Admitted to bar, Korea, 2015

    ISO 37001 ABMS (anti-bribery management system) Certification Institute, 2017


Languages
  •    Korean and English





Anti-Corruption & Corporate Compliance ,  Life Sciences and Healthcare ,  Discovery ,  ESG (Environmental, Social and Governance) ,  Corporate Investigations & White Collar Defense ,  Antitrust & Competition ,  Litigation